June 28, 2012(Washington, D.C.) – Today, the Council for Citizens Against Government Waste (CCAGW) President Tom Schatz issued the following statement in response to the United States Supreme Court’s 5-4 decision to uphold the Patient Protection and Affordable Care Act (Obamacare).
This post was imported from a legacy archive. Please excuse any formatting inconsistencies.
On June 27, 2012. Age 55. Of Bellmawr, NJ and formerly of Berlin, NJ. Passed away at home.
Loving son of the late Joseph J. Mulderig, Sr. and Rita M. (nee McConnell). Dear brother of Rita Toy (nee Mulderig) and her husband Edward, and Maureen Glezman (nee Mulderig) and her husband, the late Daniel Glezman. Devoted uncle to David Glezman, Patrick Glezman, Mandie Walker (fiancé of Patrick), Kathleen Toy and the late Edward. E. \”Ted\” Toy, Jr. Great uncle to Maclian and Rawley Glezman. Lifelong friend to Joseph Wadsworth and family of Williamstown, NJ.
Joseph was born in Philadelphia, PA, raised in Berlin, NJ and was a graduate of Paul VI High School in Haddonfield, NJ. He enlisted in the Navy after high school and served for four years. Upon returning home, Joseph enrolled in Rutgers University in Camden, and left before completing for a position with the United States Post Office where he was employed until his death. Joseph made many friends during his tenure with the USPS and he is remembered fondly by the coworkers who knew him. He was a member of the Brooklawn American Legion, the VFW Post #9563 and ventured on a retreat each year with the Men of Malvern.
This post was imported from a legacy archive. Please excuse any formatting inconsistencies.
![\"English:](\"https://commons.wikipedia.org/wiki/File:Ogco_fda_1006.jpg\")
English: Logo of the U.S. Food and Drug Administration (2006) (Photo credit: Wikipedia)
FDA Press Release
Researchers at the Food and Drug Administration (FDA) have taken a close look at the long-term benefit of bisphosphonates, a class of medications widely prescribed to treat osteoporosis.
An FDA review of clinical studies measuring the effectiveness of long-term bisphosphonates use shows that some patients may be able to stop using bisphosphonates after three to five years and still continue to benefit from their use, says Marcea Whitaker, M.D., a medical officer at FDA’s Center for Drug Evaluation and Research. Whitaker is one of the co-authors of the FDA review, which was published in the May 31, 2012 issue of The New England Journal of Medicine.
This post was imported from a legacy archive. Please excuse any formatting inconsistencies.